NicOx announced the terms of its rights issue to advance the lead product naproxcinod, for treating osteoarthritis, and its broader portfolio broader, fixing the new shares at Euros 14.20 each.
The company is offering 9,131,526 new ordinary shares and expects to raise approximately Euros130 million. The new shares will represent 24 percent of the equity.
Follow where the public and private R&I money is going and which collaborative opportunities you can pursue.
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening.
Sign up for the Funding Newswire
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
